Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $45 to $52.
February 29, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney has maintained an Outperform rating on Crinetics Pharmaceuticals and increased the price target from $45 to $52.
The increase in price target by Baird, a reputable financial firm, suggests a strong confidence in Crinetics Pharmaceuticals' future performance. This positive analyst rating and raised target are likely to instill investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100